Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
Abstract Background Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer’s disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (Tf...
Main Authors: | Stina Syvänen, Greta Hultqvist, Tobias Gustavsson, Astrid Gumucio, Hanna Laudon, Linda Söderberg, Martin Ingelsson, Lars Lannfelt, Dag Sehlin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-018-0377-8 |
Similar Items
-
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
by: Fadi Rofo, et al.
Published: (2021-09-01) -
Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils
by: S. Ekmark-Lewén, et al.
Published: (2023-01-01) -
Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
by: Veronica Lindström, et al.
Published: (2014-09-01) -
The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death
by: Sofia Söllvander, et al.
Published: (2018-03-01) -
An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
by: Anna Lord, et al.
Published: (2009-12-01)